FDA continues to struggle with implications of approving Sarepta’s drugs

FDA continues to struggle with implications of approving Sarepta’s drugs

STAT Plus: The FDA continues to struggle with the implications of approving Sarepta’s drugs

By MATTHEW HERPER

KRISTOFFER TRIPPLAAR/SIPA VIA AP

New documents lay bare the stark divide within the FDA regarding the approval of a Sarepta medicine to treat boys with Duchenne muscular dystrophy.

READ MORE